Radicle Clarity RPN: A Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes.

NCT ID: NCT07219641

Last Updated: 2025-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

750 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-05

Study Completion Date

2027-01-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Radicle Clarity RPN: A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States.

Eligible participants will (1) have the opportunity for meaningful improvement (at least 30%) in their primary health outcome and (2) express acceptance in taking a product and not knowing its formulation until the end of the study.

Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded.

Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Function

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants will be stratified based on their age, assigned sex at birth and health outcome score during enrollment, then randomized to one of the study arms. Each participant will have an equal chance of being assigned to any study arm.
Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators
The investigator is blinded to the participants' assigned study products. Participants are blinded to the study product they received.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo Control

Clarity Product Placebo Control

Group Type PLACEBO_COMPARATOR

Clarity Product Placebo Control

Intervention Type DIETARY_SUPPLEMENT

Participants will use their Clarity Product Placebo Control as directed for a period of 6 weeks.

Active Product 1

Clarity Active Product 1

Group Type EXPERIMENTAL

Clarity Active Product 1

Intervention Type DIETARY_SUPPLEMENT

Participants will use their Clarity Active Product 1 as directed for a period of 6 weeks.

Active Product 2

Clarity Active Product 2

Group Type EXPERIMENTAL

Clarity Active Product 2

Intervention Type DIETARY_SUPPLEMENT

Participants will use their Clarity Active Product 2 as directed for a period of 6 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clarity Product Placebo Control

Participants will use their Clarity Product Placebo Control as directed for a period of 6 weeks.

Intervention Type DIETARY_SUPPLEMENT

Clarity Active Product 1

Participants will use their Clarity Active Product 1 as directed for a period of 6 weeks.

Intervention Type DIETARY_SUPPLEMENT

Clarity Active Product 2

Participants will use their Clarity Active Product 2 as directed for a period of 6 weeks.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Participants must meet all the following criteria:

* Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities.

* Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed.
* Resides in the United States.
* Has the opportunity for at least 30% improvement in their primary health outcome.
* Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study.

* Exclusion

Individuals who report any of the following during screening will be excluded from participation:

* Report being pregnant, trying to become pregnant, or breastfeeding.
* Unable to provide a valid US shipping address and mobile phone number.
* Reports current enrollment in another clinical trial.
* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day).
* Unable to read and understand English.
* Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.

* NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure.
* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.

* Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products.
* Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products.
* Lack of reliable daily access to the internet.
Minimum Eligible Age

21 Years

Maximum Eligible Age

105 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Radicle Science

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Susan Hewlings

Role: PRINCIPAL_INVESTIGATOR

Radicle Science

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Radicle Science Inc.

Del Mar, California, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Study Manager

Role: CONTACT

Phone: 858-779-0086

Email: [email protected]

Susan Hewlings

Role: CONTACT

Phone: 760-281-3898

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Study Manager

Role: primary

Megan Mosely

Role: backup

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RADX_P_2406_RPN

Identifier Type: -

Identifier Source: org_study_id